Clinical Trial Update: Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of once-daily controlled-release pregabalin for postherpetic neuralgia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• Pregabalin (Pregabalin)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Post Herpetic Neuralgia | Phase 3 | Status: COMPLETED | Results posted: 2016-01-13